- Home
- USEA vs AEON Comparison
USEA vs AEON Comparison
Compare USEA & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | AEON |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Greece | United States |
| Employees | N/A | 8 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 19.0M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | USEA | AEON |
|---|---|---|
| Price | $2.63 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 65.1K | ★ 662.7K |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.26 |
| 52 Week High | $2.82 | $1.45 |
Technical Indicators
Market Signals| Indicator | USEA | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 18.70 |
| Support Level | $2.50 | N/A |
| Resistance Level | $2.63 | $1.12 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 31.25 | 6.82 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.